Eli Lilly said its obesity pill Foundayo significantly reduced the severity of obstructive sleep apnea in patients with obesity in a late-stage trial. The company announced the results on Monday.

Lilly plans to file with the U.S. Food and Drug Administration by the end of the year for approval of the daily pill for moderate-to-severe obstructive sleep apnea, or OSA, in adults who have obesity or are overweight. Foundayo rolled out in the U.S. in April.

The trial tested the drug in two studies. The first included 363 patients who were unable or unwilling to use positive airway pressure, or PAP, therapy. The second included 349 patients who were already using PAP therapy.

In patients not using PAP therapy, Foundayo reduced the apnea-hypopnea index, which measures how many times per hour breathing is restricted or blocked, by an average of 21.1 events per hour at 52 weeks. The placebo group saw an average reduction of 4.8. Lilly said the overall AHI reduction was 43.8% for Foundayo, compared with 6.3% for placebo. The company said 31.5% of participants on Foundayo met criteria for remission or improvement to mild OSA.

In patients also using PAP therapy, Foundayo reduced AHI by an average of 18.3 events per hour at 52 weeks, compared with 5.5 for placebo. Lilly said the overall reduction was about 27.5%, compared with 3% for placebo. The company said 19.6% of participants in that group met criteria for remission or mild OSA.

Lilly said patients lost roughly 11% of their weight across groups at 52 weeks. The company also said the pill lowered a marker of inflammation.

Discontinuation due to side effects was higher with Foundayo than with placebo. About 12% of patients not using PAP therapy stopped the drug, compared with 3.8% on placebo. In the PAP group, 6.8% stopped Foundayo, compared with 0.6% on placebo. Lilly said the most common side effects were gastrointestinal, including nausea, diarrhea, constipation and vomiting, and were generally mild to moderate.

Lilly's Zepbound became the first medication to win U.S. approval for OSA in December 2024, according to the report.